PPT-Ariana Beck, M.D. PGY3 HIV and Transfusion:

Phylogeny and Transfusion Objectives Introduction and background information History of HIV and HIV phylogeny Current US HIV epidemiology and blood supply testing CDC published data Current Global HIV epidemiology and blood supply testing . By Evan Ewing. General Facts. Historical Time Period: The western frontier expansion. Lived from 1788-1866. Studied at the University of Berlin. Got Ph.D. from the University of Tubingen. Important Accomplishments. presented by . Dr Azza Serry. Blood transfusion. . Blood . is a precious as the only source is the human being , so handling of the blood should be conducted with the deserved dignity and administered in its proper indication . . Lyle R. Petersen, MD, MPH. Brad Biggerstaff, PhD. Division of Vector-Borne Diseases. Centers for Disease Control and Prevention. Blood Products Advisory Committee Meeting. December 14, 2010. Agenda. Arbovirus risk model. An Evidence-Based . Approach. Haneen . Yasin. Abdella, MD. Hematology Oncology . Kidz. Medical Services. Miami Children’s Hospital. Objectives. Review the definite indications for . leukoreduced. Individualisierungstheorie. Von: Lukas Autor und Julius Ullrich. Inhaltsverzeichnis . Einleitung. Was ist Individualisierung. ?. Individualisierung nach Beck in der . Gesellschaft. Individualisierungstheorie/ die drei Dimensionen. Which is the Culprit for Worse Outcomes in Cardiac Surgery?. Damien J. LaPar MD, MSc, James M. Isbell MD, MSCI, Jeffrey B. Rich MD, . Alan M. . Speir. MD, Mohammed . Quader. , MD, Irving L. . Kron. MD, . Reduce Complications of . Prematurity. . A . Multi-site Quality Improvement Project. Sponsored . by the Indiana State Department of . Health. . Presenter: Sandra Hoesli, MD, MS. Objectives. Describe the Indiana Vermont Oxford Network Quality Collaborative (. Elizabeth S. Allen, MD. Outline. Platelets. Problems with Platelets. Pathogen Reduced Platelets. UCSD Implementation Strategy. Objectives. Understand the risks of conventional platelet transfusion. Describe the mechanism and effects of pathogen reduction technology. Can you confidently abandon CMV seronegative products in the modern era of pre-storage leukoreduction?. Jeannie Callum, BA, MD, FRCPC. Really?. Are we still talking. about this in 2017?. Disclosure. 51 yrs old female patient. In ICU, POD 2 after MVrepair. isoproterenol/dopamine for junctional rhythm. BP 105/60, HR 75/min, CVP 5. ABG: normal. NC 4l O. 2. Mobilized. HCT 25.5% . → I unit of RBC → Hct 29%. for Red Blood Cell Transfusion. Based on the Patient Blood Management Guidelines. Every . ONE . matters. Patient Blood Management Guidelines. www.blood.gov.au. . www.blood.gov.au/pbm-guidelines. . Single Unit. below is notmprehensive list it is representative of some common Blood FractionsexamplesInitial only those that you or the patientwill acceptProduct/Treatment Involving the Use of One146s Own Blood C Infusion of . blood products . for the purpose of restoring circulating volume.. Administration . of blood and blood components requires knowledge of correct administration techniques and possible complications. .” . . –Robert Beal, past director of International Federation of Red Cross. Transfusions: History. 1660s: First experiments in blood transfusion, transfused dog blood to humans. Patient died and experiments were banned..